top of page

BIO-Europe 2025: AAVantgarde Bio, which is working on gene therapies for inherited retinal diseases that are caused by mutations in large genes, closed a $141M series B raise today

Nov 3, 2025
1 min read

CEO Natalia Misciattelli describes the lead programs for Stargardt Disease and Usher 1B Syndrome, and how AAVantgarde is able to solve the problem of delivering genes that are naturally too large for single AAV vectors.




Coverage brought to you by:


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro_Logo_2023_Primary-4.png

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

bottom of page